Emcure halves price of its semaglutide weight loss drug Poviztra after Novo Nordisk patent expiry — check new rates
Emcure Pharmaceuticals announced Thursday that it is halving the price of its weight management drug Poviztra, a semaglutide injection, in a move aimed at making obesity treatment more affordable for patients.
The company said the starting dose of Poviztra will now be priced as follows: ₹dropped to 3,999 per month ₹8,790 before. Meanwhile, prices for higher doses fell by an average of 47%.
The revised rates will come into force from April 3, 2026, the company said.
The announcement comes just weeks after Danish drugmaker Novo Nordisk lost patent protection in India for semaglutide, the molecule behind blockbuster weight loss drugs such as Ozempic and Wegovy.
This triggered a wave of launches by domestic pharmaceutical companies introducing cheaper copies or generics, triggering a competitive onslaught that led to drug prices falling by more than half.
Investment bank Jefferies has called it a potential “magic pill moment” for India, estimating that the semaglutide market could reach $1 billion domestically with the right pricing and uptake, according to a report by BBC.
Proviztra price cut: Check revised monthly rates
Emcure Pharmaceuticals has reduced monthly prices for its weight-loss drug Poviztra across all doses. Here are the revised prices:
- Poviztra 0.25 mg: Price dropped ₹8,790 to ₹3,999
- Poviztra 0.5 mg: Price dropped ₹11,200 to ₹4,999
- Poviztra 1 mg: Price dropped ₹11,200 to ₹5,999
- Poviztra 1.7 mg: Price dropped ₹13,000 to ₹7,999
- Poviztra 2.4 mg: Price dropped ₹15,000 to ₹8,999
According to the company, the price revision will bring the innovative molecule, supported by robust clinical and real-world evidence, to a significantly larger patient base nationwide.
The company’s official statement stated that this development comes at a time when obesity and weight-related health problems have emerged as one of India’s most pressing public health problems.
“Poviztra’s revised pricing is a step towards making scientifically validated weight management treatments more accessible and affordable to a broader patient base,” said Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharmaceuticals.
India’s pharmaceutical industry is currently worth around $60 billion and is expected to double by 2030. Much of this growth comes from the country’s strong production of generic drugs, the BBC reported.
Power is now leading to intense competition around semaglutide, a drug used for weight loss and treating diabetes. Until recently, the injection was quite expensive and was used mostly by wealthy patients. However, the report stated that the treatment may soon become much more widespread as more Indian companies enter the market and prices fall.
Originally developed to treat diabetes, these drugs are now widely used as a game-changing weight loss treatment, offering results that few previous treatments can match. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.
